4th Quarter - Report

TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 444, 340B Program Improvement Integrity Act; 340B program issues; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness; H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B program issues, regulatory approval for follow-on biologics, drug labeling, access to clinical trials, importation [S.A. 2793], health reform issues generally; H.R. 3962, Affordable Health Care for America Act: regulatory approval for follow-on biologics, 340B program issues, comparative effectiveness, importation, health reform issues generally; S. 422, The Heart Disease Education, Analysis Research, and Treatment (HEART) for Women Act: new drug application requirements; S. 488, Access to Cancer Clinical Trials Act of 2009: access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 914, Cures Acceleration Network and National Institutes of Health Reauthorization of 2009: basic research and development; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory approval pathway for follow-on biologics, 340B program issues, importation; S. 1796, America's Health Future Act of 2009: comparative effectiveness, importation, health reform issues generally

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 726 (111th), H.R. 1298 (111th), H.R. 1427 (111th), H.R. 2502 (111th), H.R. 1548 (111th), S. 1142 (111th), S. 1213 (111th), S. 1679 (111th), S. 422 (111th), H.R. 444 (111th), S. 914 (111th), S. 525 (111th), S. 488 (111th), H.R. 2824 (111th), H.R. 3590 (111th), S. 1232 (111th), H.R. 3962 (111th), S. 1796 (111th)

Copyright/Patent/Trademark CPT

H.R. 573, To amend the Federal Food , Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions; H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements; H.R. 3590, Patient Protection and Affordable Care Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics, patent settlements, and authorized generics; H.R. 3962, Affordable Health Care for America Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics, and patent settlements; S. 369, Preserve Access to Affordable Generics Act: patent settlements; S. 501, To amend the Federal Food, Drug, and Cosmetics Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions; S. 515, Patent Reform Act of 2009: reforms of the patent laws; S. 610, Patent Reform Act of 2009: reforms of the patent laws: S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; International intellectual property issues

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1706 (111th), S. 726 (111th), S. 515 (111th), S. 610 (111th), H.R. 573 (111th), H.R. 3962 (111th), H.R. 1260 (111th), S. 369 (111th), H.R. 3590 (111th), H.R. 1427 (111th), S. 501 (111th), H.R. 1548 (111th)

Medicare/Medicaid MMM

H.R. 3590, Patient Protection and Affordable Care Act: Part D coverage gap discounts, Part D rebates, Part D issues generally, Medicare payment issues, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform fee and health reform issues generally; H.R. 3962, Affordable Health Care for America Act: Part D coverage gap, Part D rebates, Part D issues generally, Medicaid rebate issues, transparency issues, comparative effectiveness, health reform issues generally; S. 1796, America's Healthy Future Act of 2009: Part D coverage gap discounts, Part D issues generally, Medicare payment issues, Medicaid rebate issues, comparative effectiveness, health reform fee, health reform issues generally

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3962 (111th), H.R. 3590 (111th), S. 1796 (111th)

Budget/Appropriations BUD

H.R. 2982, Department of Homeland Security Appropriations Act, 2010: importation; H.R. 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding; S. 1298, Department of Homeland Security Appropriations Act, 2010: importation; S. 1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding; H.R. 3288, Consolidated Appropriations Act: comparative effectiveness, NIH funding, pandemic funding

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2997 (111th), H.R. 3288 (111th), S. 1406 (111th), H.R. 2982 (111th), S. 1298 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.